Results 111 to 120 of about 28,855 (210)

AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist. [PDF]

Pharmacol Res Perspect
Patel M, Ganeshan D, Horgan I, Partington H, Glass M.   +4 more
europepmc   +1 more source

Global Prevalence of Self‐Reported Alarm Features in the General Population and Among Individuals With Disorders of Gut–Brain Interaction—Results From the Rome Foundation Global Epidemiology Study

United European Gastroenterology Journal, Volume 14, Issue 7, September 2026.
ABSTRACT Background Data on the global prevalence of alarm features in the general population and among individuals with disorders of gut–brain interaction (DGBI) are limited. Methods We analysed data from the Rome Foundation Global Epidemiology Study to estimate the prevalence of fourteen self‐reported alarm features in the global population and among
Jessica Sjölund, Jóhann P. Hreinsson, Brian E. Lacy, Hans Törnblom, Shrikant I. Bangdiwala, Olafur S. Palsson, Ami D. Sperber, Magnus Simren   +7 more
wiley   +1 more source

Cannabinoid receptor expression profiling in lymphocyte subsets reveals clinically relevant immune patterns in SLE. [PDF]

Front Immunol
Rosero AM, Rios-Serna LJ, Cañas CA.
europepmc   +1 more source

Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 659-674, September 2026.
Fatigue is common and burdensome in disorders of gut‐brain interaction and increases with diagnostic overlap. In this global population‐based study, fatigue was associated with female sex, age, BMI, sleep disturbance, higher anxiety and depression scores, greater somatic symptom burden, lower psychological well‐being, antidepressant use, and greater ...
Fleur Veldman, Francesco Innocenti, Imran Aziz, Asma Fikree, Shrikant I. Bangdiwala, Olafur Palsson, Ami D. Sperber, Daniel Keszthelyi   +7 more
wiley   +1 more source

Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders. [PDF]

Biomedicines
Faganeli D, Lipnik-Stangelj M.
europepmc   +1 more source

Cannabinoid and adenosine A2A receptor crosstalk regulates postnatal and adult hippocampal neurogenesis

British Journal of Pharmacology, Volume 183, Issue 18, Page 5440-5457, September 2026.
Background and purpose Adult neurogenesis is a tightly regulated process affected by both cannabinoid receptors (CB1 and CB2) and adenosine 2A (A2A) receptors, both of which modulate neural progenitor cell activity. While emerging evidence suggests an interaction between these neuromodulatory systems, the extent and mechanism of their interplay in ...
Rui S. Rodrigues, Adam Armada‐Moreira, Laura Gómez‐Acero, Filipa F. Ribeiro, Francisco M. Mouro, Ana M. Sebastião, Francisco Ciruela, Ester Aso, Sara Xapelli   +8 more
wiley   +1 more source

Alcohol and Cannabinoids Differentially Regulate Macrophage Polarization, with Co-Exposure Producing an Antagonistic Immunomodulatory Effect. [PDF]

Int J Mol Sci
Shake EP, Vargas Santos G, Sivaraman V.
europepmc   +1 more source

Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats

British Journal of Pharmacology, Volume 183, Issue 18, Page 5458-5475, September 2026.
Abstract Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission.
Carlos Núñez‐de la Calle, Lluna Careaga, Stefanie Malan‐Müller, Álvaro del Río‐García, Yaiza Trueba, Leticia Gil de Biedma‐Elduayen, Nuria Morales‐Puerto, Rebeca Vidal, Åsa Wiman, Sophie Erhardt, María Dolores Gutiérrez‐López, Esther O'Shea, María Isabel Colado   +12 more
wiley   +1 more source

Cannabinoids in Alzheimer's disease: animal-human evidence and clinical pharmacology challenges. [PDF]

Front Behav Neurosci
Komedera M, Wojda U, Kiryk A.
europepmc   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source